Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction

Bioorganic & Medicinal Chemistry Letters
2004.0

Abstract

In a continuing effort to discover novel chemotypes as potent and selective PDE5 inhibitors for the treatment of male erectile dysfunction (ED), we have found that 4-benzylaminoquinoline derivatives are very potent and selective PDE5 inhibitors. Some compounds in this series had PDE5 IC(50)'s as low as 50 pM. While an electron withdrawing group at the C6-position of the quinoline substantially improved PDE5 potency, an ethyl group at the C8-position not only improved the PDE5 potency but also the isozyme selectivity. Substitutents at the C3-position can incorporate a variety of different groups. The synthesis and primary structure-activity relationship of this new series of potent PDE5 inhibitors are described.

Knowledge Graph

Similar Paper

Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction
Bioorganic & Medicinal Chemistry Letters 2004.0
Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction
Bioorganic & Medicinal Chemistry Letters 2008.0
2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6
Bioorganic & Medicinal Chemistry Letters 2009.0
N-3-Substituted Imidazoquinazolinones:  Potent and Selective PDE5 Inhibitors as Potential Agents for Treatment of Erectile Dysfunction
Journal of Medicinal Chemistry 2000.0
Furoyl and Benzofuroyl Pyrroloquinolones as Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction
Journal of Medicinal Chemistry 2003.0
Pyrimidinylpyrroloquinolones as Highly Potent and Selective PDE5 Inhibitors for Treatment of Erectile Dysfunction
Journal of Medicinal Chemistry 2002.0
Optimization of Substituted N-3-Benzylimidazoquinazolinone Sulfonamides as Potent and Selective PDE5 Inhibitors
Journal of Medicinal Chemistry 2000.0
Discovery of potent, selective, and orally bioavailable PDE5 inhibitor: Methyl-4-(3-chloro-4-methoxybenzylamino)-8-(2-hydroxyethyl)-7-methoxyquinazolin-6-ylmethylcarbamate (CKD 533)
Bioorganic & Medicinal Chemistry Letters 2010.0
Novel, Potent, and Selective Phosphodiesterase 5 Inhibitors:  Synthesis and Biological Activities of a Series of 4-Aryl-1-isoquinolinone Derivatives
Journal of Medicinal Chemistry 2001.0
Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity
Journal of Medicinal Chemistry 1994.0